About Cell ID
Cell ID was set up on 1st March 2013. It has done over one and half years of medical devices research via platform technologies that could be integrated with each others and provide superior diagnostics performance not only to shorten diagnostics time, improved diagnostics quality via reducing potential human-induced errors through our countless data collections and cloud storage capabilities, but also help to release limited lab resource and instruments for better utilization and improved lab productivity and efficiency. More importantly, products are GREEN, DISPOSABLE, and AFFORDABLE.
Our main development is focusing on early diseases diagnosing via cell & molecular detection through our proprietary Disposable PCR technologies. With Cell ID an R&D, manufacturing, marketing, branding and distribution under one roof, We strive to provide fast, accurate and affordable Point-Of-Care (POC) solutions for the diagnostics World with our patented platform solutions: Smart Lateral Flow, Smart Microfluidic and Integrated Platform technologies with Printed Biosensors, Printed Ultra-low Power Heater and Reagents Printing Technologies.
Other activities since we are incorporated, includes:
ACA Investments Pte Ltd (Private Equity Fund Management) is the investor of Cell ID Pte Ltd
Concluded a major licensing agreement to utilize a newly discovered antibody for the early detection of breast cancer via one of our platform technologies
Received Capability Development Grant (CDG) from SPRING on June 2015
Approved T-up Program by Spring & A*Star on Aug 2016
We are ISO 13485-2016 Certified
Till date, 7 inventions has been filed in more than 10 countries each.
One Patent Granted by United State of America on 12th Jun 2018
There is a significant demand towards near-field or bedside patients care, also know as near-field Point-of-Care (nf-POC). From in the hospitals to physicians' office, clinics or even at home, etc. The aim is to help reduce unnecessary waiting time and at the same time encourage more self-diagnostic activities within the people in the community. Hence helping patients make better-informed decisions about individuals’ health. Infectious and chronic diseases related POC kits are now one of the few most fast growing segments. Availability of rapid random access cell and molecular diagnostics application for critical care infectious diseases such as HIV, Dengue fever and chronic diseases such as cancers are likely to be the driver of near-field POC industry.
While healthcare delivery is moving towards the home base and decentralized settings such as rapid test clinics, it is driven by point-of-care diagnostics that provide accurate and directional results from traditional analog testing to affordable digital testing World, where advance smart POC diagnostics kits, for example, can be administrated and be predictably effective. In the recent years, point-of–care diagnostics have slowly replaced conventional laboratory testing due to its technological advancement over the past several years and have had helped point of care testing (POCT) to grow with double digit CAGR from 2009 to 2011 and evolve into a vital diagnostic tool. It is predicted that point of care testing market will be approximate US$ 25 Billion by 2016.
Being a primary focus on POC diagnostics’ device design and technology development start-up company, Cell ID continues to develop its proprietary “Platform Base” in-vitro POC product portfolios, which, utilizes microfluidics technology with printed biosensor and printed heater. Product technology includes "Reader-less" HbA1c POC kit, Smart HIV and hCG test kits. Integrated diagnostics test chips via cell & molecular detection for chronic diseases such as breast cancer and rest. All products also equip with auto data collection capability.
Through recycling and leveraging mature and proven technology large format printing, screening and flexo printing for example, to drive manufacturing and capital investment costs to its lowest possible plus, integrating conventional diagnostics test procedures with available enzymes, assyas, probes solutions' onto our innovative platform base testing devices. The aim is to develop a series of simple to use, affordable in cost and disposable in-vitro near field diagnostics POC devices to promote regular health screening, especially in the developed countries where lifestyle induced diseases has increased due to the leak of frequent exercise for example. Others include developing countries where basic healthcare services are not readily available and reach due to poverty for example.
Our Clinical Partners
Agencies & Institutions Supported Us
Strive to provide solutions (Speed, Accuracy, and Affordability Cost) via combinations of engineering with biological sciences, to challenge traditional lab bounded diagnostics test with affordable and near-field Point-Of-Care (nf-POC) solutions. Aim to free/release limited lab resources for better utilization, help improve lab productivity and administrations efficiency and at the sametime promote frequent self-diagnosis in the community space.